Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but the efficacy is variable. Here, we report two pa...
Main Authors: | Yingxin Sun, Yifeng Cai, Jia Chen, Jiannong Cen, Mingqing Zhu, Jinlan Pan, Depei Wu, Aining Sun, Suning Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.753842/full |
Similar Items
-
Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53
by: Qian Wang, et al.
Published: (2020-01-01) -
Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
by: Luo S, et al.
Published: (2020-10-01) -
VEGF Regulation of Angiogenic Factors via Inflammatory Signaling in Myeloproliferative Neoplasms
by: Tijana Subotički, et al.
Published: (2021-06-01) -
Novel therapeutics in myeloproliferative neoplasms
by: Sangeetha Venugopal, et al.
Published: (2020-12-01) -
Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
by: Graeme Greenfield, et al.
Published: (2020-09-01)